Autobio Diagnostics Company Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
5,700
- Stock Symbol
-
603658
- Investments
-
6
- Share Price
-
$5.73
- (As of Thursday Closing)
Autobio Diagnostics Company General Information
Description
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company's main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.
Contact Information
Website
www.autobio.com.cnCorporate Office
- Number 199, 15th Avenue
- Zhengzhou Economic and Technological Development Zone
- Zhengzhou, Henan 450016
- China
Corporate Office
- Number 199, 15th Avenue
- Zhengzhou Economic and Technological Development Zone
- Zhengzhou, Henan 450016
- China
Autobio Diagnostics Company Stock Performance
As of 12-Nov-2026, Autobio Diagnostics Company’s stock price is $5.73. Its current market cap is $3.27B with 571M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.73 | $5.85 | $4.15 - $6.01 | $3.27B | 571M | 4.73M | $0.27 |
Autobio Diagnostics Company Financials Summary
As of 30-Sep-2026, Autobio Diagnostics Company has a trailing 12-month revenue of $629M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,740,356 | 2,790,641 | 3,450,186 | 4,755,506 |
| Revenue | 629,476 | 587,710 | 623,124 | 628,089 |
| EBITDA | 172,808 | 235,579 | 246,473 | 257,716 |
| Net Income | 153,147 | 148,515 | 166,463 | 172,079 |
| Total Assets | 1,840,315 | 1,756,503 | 1,626,699 | 1,629,949 |
| Total Debt | 6,416 | 8,450 | 75,203 | 102,017 |
Autobio Diagnostics Company Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Autobio Diagnostics Company Patents
Autobio Diagnostics Company Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026138858-A1 | Method and apparatus for identifying difficult-to-differentiate bacterial species, device, and medium | Pending | 24-Dec-2024 | ||
| WO-2023169351-A1 | Composite serum matrix quality control product of three gastric function indictors, and preparation method therefor | Inactive | 09-Mar-2022 | ||
| WO-2023103827-A1 | Thyroid stimulating hormone receptor antigen reagent and thyroid stimulating hormone receptor antibody quantitative test kit | Inactive | 07-Dec-2021 | ||
| WO-2022068746-A1 | Composite sputum digestion liquid | Inactive | 29-Sep-2020 | ||
| WO-2022068751-A1 | Method for digesting sputum sample | Inactive | 29-Sep-2020 | G01N1/28 |
Autobio Diagnostics Company Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Autobio Diagnostics Company Investments (6)
Autobio Diagnostics Company’s most recent deal was a Early Stage VC with Renke Biotech. The deal was made on 31-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Renke Biotech | 31-Jul-2024 | Early Stage VC | Diagnostic Equipment | ||
| Meili Tech | 26-Apr-2023 | Later Stage VC | Diagnostic Equipment | ||
| Corey Technology | 23-Feb-2022 | Later Stage VC | Electronic Equipment and Instruments | ||
| Mobidiag/Autobio (Joint Venture) | 03-Jun-2019 | Joint Venture | Laboratory Services (Healthcare) | ||
| Mobidiag | 17-Dec-2018 | Corporate | Diagnostic Equipment |
Autobio Diagnostics Company ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.8 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Autobio Diagnostics Company Exits (1)
Autobio Diagnostics Company’s most recent exit was on 17-Dec-2018 from Mobidiag. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Mobidiag | 17-Dec-2018 | Completed |
|
Autobio Diagnostics Company FAQs
-
When was Autobio Diagnostics Company founded?
Autobio Diagnostics Company was founded in 1998.
-
Where is Autobio Diagnostics Company headquartered?
Autobio Diagnostics Company is headquartered in Zhengzhou, China.
-
What is the size of Autobio Diagnostics Company?
Autobio Diagnostics Company has 5,700 total employees.
-
What industry is Autobio Diagnostics Company in?
Autobio Diagnostics Company’s primary industry is Diagnostic Equipment.
-
Is Autobio Diagnostics Company a private or public company?
Autobio Diagnostics Company is a Public company.
-
What is Autobio Diagnostics Company’s stock symbol?
The ticker symbol for Autobio Diagnostics Company is 603658.
-
What is the current stock price of Autobio Diagnostics Company?
As of 12-Nov-2026 the stock price of Autobio Diagnostics Company is $5.73.
-
What is the current market cap of Autobio Diagnostics Company?
The current market capitalization of Autobio Diagnostics Company is $3.27B.
-
What is Autobio Diagnostics Company’s current revenue?
The trailing twelve month revenue for Autobio Diagnostics Company is $629M.
-
What is Autobio Diagnostics Company’s annual earnings per share (EPS)?
Autobio Diagnostics Company’s EPS for 12 months was $0.27.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
